Novo Holdings is set to gain unconditional EU antitrust approval for its planned $16.5 billion takeover of U.S. contract drug ...

The European Commission is expected to give unconditional approval for the $16.5 billion purchase of Catalent (NYSE: CTLT) as ...

Novo Holdings, the controlling shareholder of Novo Nordisk (NVO), is slated to received unconditional EU antitrust approval for its proposed ...

EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...

Swiss biotech Alentis Therapeutics has secured $181.4 million, money that will be used to launch clinical trials for two ...

With nearly $14 billion sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO). A Scandinavian economic behemoth ...

This health news summary explores various pharmaceutical developments including Novo Nordisk's phasing out of insulin pens, a ...

EU antitrust regulators are set to clear without conditions Novo Holdings' planned $16.5 billion takeover of Catalent, a ...

Catalent (NYSE:CTLT) rose 2% amid a report that the European Union's antitrust regulator will likely grant approval for its ...

BRUSSELS/LONDON, Nov 22 (Reuters) - Novo Holdings is set to gain unconditional EU antitrust approval for its planned $16.5 billion takeover of U.S. contract drug maker Catalent (CTLT.N), opens new ...